1. Home
  2. GDOT vs ABUS Comparison

GDOT vs ABUS Comparison

Compare GDOT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Green Dot Corporation $0.001 par value

GDOT

Green Dot Corporation $0.001 par value

N/A

Current Price

$12.22

Market Cap

703.2M

Sector

Finance

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$4.07

Market Cap

836.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GDOT
ABUS
Founded
1999
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
703.2M
836.0M
IPO Year
2010
2008

Fundamental Metrics

Financial Performance
Metric
GDOT
ABUS
Price
$12.22
$4.07
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $16.13
N/A
AVG Volume (30 Days)
294.4K
★ 2.8M
Earning Date
11-17-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.26
EPS
0.33
★ 0.84
Revenue
★ $2,080,491,000.00
$14,083,000.00
Revenue This Year
$15.22
$1,208.75
Revenue Next Year
$6.73
N/A
P/E Ratio
$37.18
★ $4.83
Revenue Growth
20.69
★ 128.21
52 Week Low
$10.10
$3.50
52 Week High
$13.75
$5.45

Technical Indicators

Market Signals
Indicator
GDOT
ABUS
Relative Strength Index (RSI) 42.66 36.20
Support Level $11.95 $4.10
Resistance Level $12.66 $4.57
Average True Range (ATR) 0.23 0.14
MACD 0.03 0.02
Stochastic Oscillator 38.33 19.70

Price Performance

Historical Comparison
GDOT
ABUS

About GDOT Green Dot Corporation $0.001 par value

Green Dot Corp is a financial technology company that provides financial services for consumers in the United States without good banking options. It has three segments Consumer Services, Business to Business Services(B2B), and Money Movement Services. The company generates maximum revenue from B2B segment. Its B2B Services segment consists of revenues and expenses derived from (i) its partnerships with prominent consumer and technology companies that make banking products and services available to their consumers, partners and workforce through integration with its banking platform (the "Banking-as-a-Service", or "BaaS channel"), and (ii) a comprehensive payroll platform that it offers to corporate enterprises (the "Employer channel") to facilitate payments for todays workforce.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: